Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.

Semba CP, Swearingen D, Smith VL, Newman MS, O'Neill CA, Burnier JP, Haughey DB, Gadek TR.

J Ocul Pharmacol Ther. 2011 Feb;27(1):99-104. doi: 10.1089/jop.2009.0105. Epub 2010 Mar 24.

PMID:
20334535
2.

Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.

Jackson DY, Quan C, Artis DR, Rawson T, Blackburn B, Struble M, Fitzgerald G, Chan K, Mullins S, Burnier JP, Fairbrother WJ, Clark K, Berisini M, Chui H, Renz M, Jones S, Fong S.

J Med Chem. 1997 Oct 10;40(21):3359-68.

PMID:
9341911
3.

In vitro characterization of four novel classes of growth hormone-releasing peptide.

Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE, Somers TC, Stanley MS, Cronin MJ.

Endocrinology. 1995 Dec;136(12):5694-9.

PMID:
7588325
4.

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS, Fairbrother WJ, Hammonds RG, Ingle GS, Jacobsen NE, Mortensen DL, Rawson TE, Won WB, Clark RG, Somers TC.

Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11165-9.

5.

Agonist selectivity for three species of natriuretic peptide receptor-A.

Schoenfeld JR, Sehl P, Quan C, Burnier JP, Lowe DG.

Mol Pharmacol. 1995 Jan;47(1):172-80.

PMID:
7838126
6.

Subtiligase: a tool for semisynthesis of proteins.

Chang TK, Jackson DY, Burnier JP, Wells JA.

Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):12544-8.

7.

Determination of the solution structure of the peptide hormone guanylin: observation of a novel form of topological stereoisomerism.

Skelton NJ, Garcia KC, Goeddel DV, Quan C, Burnier JP.

Biochemistry. 1994 Nov 22;33(46):13581-92.

PMID:
7947768
8.

Synthetic chimeras of mouse growth factor-associated glandular kallikreins. I. Kinetic properties.

Blaber M, Isackson PJ, Burnier JP, Marsters JC Jr, Bradshaw RA.

Protein Sci. 1993 Aug;2(8):1210-9.

9.

Tetrapeptide inhibitors of protein farnesyltransferase: amino-terminal substitution in phenylalanine-containing tetrapeptides restores farnesylation.

Brown MS, Goldstein JL, Paris KJ, Burnier JP, Marsters JC Jr.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8313-6.

10.

Characterization of the recombinant human receptor for Escherichia coli heat-stable enterotoxin.

de Sauvage FJ, Horuk R, Bennett G, Quan C, Burnier JP, Goeddel DV.

J Biol Chem. 1992 Apr 5;267(10):6479-82.

11.

Substrate specificities of growth factor associated kallikreins of the mouse submandibular gland.

Blaber M, Isackson PJ, Marsters JC Jr, Burnier JP, Bradshaw RA.

Biochemistry. 1989 Sep 19;28(19):7813-9.

PMID:
2611215
12.

Engineering subtilisin BPN' for site-specific proteolysis.

Carter P, Nilsson B, Burnier JP, Burdick D, Wells JA.

Proteins. 1989;6(3):240-8.

PMID:
2516317
13.

Probing steric and hydrophobic effects on enzyme-substrate interactions by protein engineering.

Estell DA, Graycar TP, Miller JV, Powers DB, Wells JA, Burnier JP, Ng PG.

Science. 1986 Aug 8;233(4764):659-63.

PMID:
17835820
14.

Computer-generated models of blood coagulation factor Xa, factor IXa, and thrombin based upon structural homology with other serine proteases.

Furie B, Bing DH, Feldmann RJ, Robison DJ, Burnier JP, Furie BC.

J Biol Chem. 1982 Apr 10;257(7):3875-82.

15.

Gamma-carboxyglutamic acid.

Burnier JP, Borowski M, Furie BC, Furie B.

Mol Cell Biochem. 1981 Sep 25;39:191-207. Review.

PMID:
6458761
16.

Inactivation of purified human alpha 2-antiplasmin and purified human C1 inhibitor by synthetic fibrinolytic agents.

Miles LA, Burnier JP, Verlander MS, Goodman M, Kleiss AJ, Griffin JH.

Blood. 1981 Jun;57(6):1015-24.

17.

[Suppurative eye diseases].

BURNIER JP.

Rev Bras Med. 1961 Sep;18:588-90. Portuguese. No abstract available.

PMID:
13874977

Supplemental Content

Loading ...
Support Center